{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:47:29Z","timestamp":1787950049115,"version":"build-2784847793"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s12325-024-03030-5","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T02:03:38Z","timestamp":1731463418000},"page":"334-347","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct03364309","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Xinghua","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuqiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuqin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaipei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinnan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songmei","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"issue":"3","key":"3030_CR1","first-page":"360","volume":"136","author":"H Huang","year":"2023","unstructured":"Huang H, Chen M, Wu W, et al. Efficacy and safety of ixekizumab in Chinese patients with plaque psoriasis. Chin Med J (Engl). 2023;136(3):360\u20131.","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"3030_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","volume":"21","author":"A Raharja","year":"2021","unstructured":"Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med (Lond). 2021;21(3):170\u20133.","journal-title":"Clin Med (Lond)"},{"key":"3030_CR3","unstructured":"Badri T, Kumar P, Oakley AM. Plaque Psoriasis. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024; Accessed 1 July 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK430879\/."},{"issue":"9993","key":"3030_CR4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CEM Griffiths","year":"2015","unstructured":"Griffiths CEM, Reich K, Lebwohl M, UNCOVER-2 and UNCOVER-3 investigators, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541\u201351.","journal-title":"Lancet"},{"key":"3030_CR5","unstructured":"Medscape. Fast Five Quiz: Plaque Psoriasis Presentation and Diagnosis. 2021. Accessed 30 April 24. Available from:https:\/\/reference.medscape.com\/viewarticle\/929579?form=fpf"},{"issue":"4","key":"3030_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/JD9.0000000000000244","volume":"5","author":"X Li","year":"2022","unstructured":"Li X, Zheng J, Pan WL, et al. Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 60-week results from a phase 3 study. Int J Dermatol Venereol. 2022;5(4):181\u201390.","journal-title":"Int J Dermatol Venereol"},{"key":"3030_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369: m1590.","journal-title":"BMJ"},{"issue":"12","key":"3030_CR8","doi-asserted-by":"publisher","first-page":"5464","DOI":"10.1007\/s12325-023-02672-1","volume":"40","author":"L Ying","year":"2023","unstructured":"Ying L, Suyun J, Yanhua L, et al. Safety and efficacy of ixekizumab in Chinese adults with moderate-to-severe plaque psoriasis: a prospective, multicenter, observational study. Adv Ther. 2023;40(12):5464\u201374.","journal-title":"Adv Ther"},{"issue":"4 Suppl 78","key":"3030_CR9","first-page":"S63","volume":"31","author":"MK Ramirez-Fort","year":"2013","unstructured":"Ramirez-Fort MK, Levin AA, Au SC, Gottlieb AB. Continuous versus intermittent therapy for moderate-to-severe psoriasis. Clin Exp Rheumatol. 2013;31(4 Suppl 78):S63-70.","journal-title":"Clin Exp Rheumatol"},{"issue":"9583","key":"3030_CR10","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/S0140-6736(07)61129-5","volume":"370","author":"A Menter","year":"2007","unstructured":"Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007;370(9583):272\u201384.","journal-title":"Lancet"},{"issue":"5","key":"3030_CR11","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1365-2133.2009.09505.x","volume":"161","author":"CH Smith","year":"2009","unstructured":"Smith CH, Anstey AV, Barker JNWN, et al. British Association of Dermatologists\u2019 guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161(5):987\u20131019.","journal-title":"Br J Dermatol"},{"issue":"2","key":"3030_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00403-015-1613-8","volume":"308","author":"C Blome","year":"2016","unstructured":"Blome C, Gosau R, Radtke MA, et al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res. 2016;308(2):69\u201378.","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"3030_CR13","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s13555-019-00334-1","volume":"9","author":"J Gorelick","year":"2019","unstructured":"Gorelick J, Shrom D, Sikand K, et al. Understanding treatment preferences in patients with moderate to severe plaque psoriasis in the USA: results from a cross-sectional patient survey. Dermatol Therapy (Heidelb). 2019;9(4):785\u201397.","journal-title":"Dermatol Therapy (Heidelb)"},{"issue":"3","key":"3030_CR14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.intimp.2013.02.018","volume":"16","author":"Y Cai","year":"2013","unstructured":"Cai Y, Fleming C, Yan J. Dermal \u03b3\u03b4 T cells- a new player in the pathogenesis of psoriasis. Int Immunopharmacol. 2013;16(3):388\u201391.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"3030_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. New Engl J Med. 2016;375(4):345\u201356.","journal-title":"New Engl J Med"},{"issue":"6","key":"3030_CR16","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/jdv.14163","volume":"31","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Sofen H, et al. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. J Eur Acad Dermatol Venereol. 2017;31(6):1004\u201313.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"3030_CR17","first-page":"573","volume":"56","author":"Committee on Psoriasis, Chinese Society of Dermatology","year":"2023","unstructured":"Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China (2023 edition). Chin J Dermatol. 2023;56(7):573\u2013625.","journal-title":"Chin J Dermatol"},{"issue":"4","key":"3030_CR18","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s13555-024-01147-7","volume":"14","author":"A Egeberg","year":"2024","unstructured":"Egeberg A, Hawkes JE, Somani N, et al. Sustained improvements in clinical and patient-reported outcomes and quality of life through 5 years among ixekizumab-treated patients with complete clearance of scalp psoriasis by week 60. Dermatol Ther (Heidelb). 2024;14(4):1007\u201318.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"3030_CR19","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/bjd.13551","volume":"172","author":"R Bissonnette","year":"2015","unstructured":"Bissonnette R, Iversen L, Sofen H, et al. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol. 2015;172(5):1395\u2013406.","journal-title":"Br J Dermatol"},{"issue":"4","key":"3030_CR20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40257-022-00679-y","volume":"23","author":"M Masson Regnault","year":"2022","unstructured":"Masson Regnault M, Shourick J, Jendoubi F, Tauber M, Paul C. Time to relapse after discontinuing systemic treatment for psoriasis: a systematic review. Am J Clin Dermatol. 2022;23(4):433\u201347.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"3030_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2015.04.011","volume":"73","author":"U Mrowietz","year":"2015","unstructured":"Mrowietz U, Leonardi CL, Girolomoni G, SCULPTURE Study Group, et al. Secukinumab retreatment- as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(1):27\u201336.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"3030_CR22","first-page":"1063","volume":"20","author":"CY Wang","year":"2021","unstructured":"Wang CY, Foley P, Baker C, Rademaker M. Biological therapy interruption and re-treatment in chronic plaque psoriasis. J Drugs Dermatol. 2021;20(10):1063\u201371.","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"3030_CR23","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1007\/s13555-024-01229-6","volume":"14","author":"CY Hsieh","year":"2024","unstructured":"Hsieh CY, Hsu FL, Tsai TF. Comparison of drug-free remission after the end of phase III Trials of three different anti-IL-23 inhibitors in psoriasis. Dermatol Ther (Heidelb). 2024;14(9):2607\u201320.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"3030_CR24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/jdv.15292","volume":"33","author":"Y Umezawa","year":"2019","unstructured":"Umezawa Y, Torisu-Itakura H, Morisaki Y, Japanese Ixekizumab Study Group, et al. Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab. J Eur Acad Dermatol Venereol. 2019;33(3):568\u201376.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"3030_CR25","first-page":"191","volume":"56","author":"Committee on Psoriasis, Chinese Society of Dermatology","year":"2023","unstructured":"Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on treat- to-target approach for the treatment of psoriasis with biological agents. Chin J Dermatol. 2023;56(3):191\u2013203.","journal-title":"Chin J Dermatol"},{"issue":"6","key":"3030_CR26","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.jaad.2021.04.093","volume":"86","author":"LR Ye","year":"2022","unstructured":"Ye LR, Yan BX, Chen XY, Chen SQ, Chen JQ, Man XY, Chinese Psoriasis Real World Evidence Research Group (CPRWERG). Extended dosing intervals of ixekizumab for psoriasis: a single-center, uncontrolled, prospective study. J Am Acad Dermatol. 2022;86(6):1348\u201350.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3030_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jaad.2019.01.035","volume":"88","author":"H-Y Chiu","year":"2023","unstructured":"Chiu H-Y, Hui RCY, Tsai T-F, et al. Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: an 8-year multicenter study. J Am Acad Dermatol. 2023;88(1):71\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3030_CR28","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jaad.2020.11.022","volume":"85","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Lebwohl MG, Mabuchi T, Leung A, Garrelts A, Crane H, et al. Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol. 2021;85(2):360\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"3030_CR29","doi-asserted-by":"publisher","first-page":"1353893","DOI":"10.3389\/fmed.2024.1353893","volume":"11","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Yang Z, Gong J, Shi D. Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a meta-analysis of randomized controlled trials. Front Med (Lausanne). 2024;11:1353893.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"3030_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13075-023-03257-7","volume":"26","author":"A Deodhar","year":"2024","unstructured":"Deodhar A, Blauvelt A, Lebwohl M, Feely M, Kronbergs A, Eberhart N, et al. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials. Arthritis Res Ther. 2024;26(1):49.","journal-title":"Arthritis Res Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03030-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03030-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03030-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T06:02:42Z","timestamp":1738216962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03030-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3030"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03030-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"assertion":[{"value":"19 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xuan Wang and Jinnan Li are employees of Eli Lilly and Company, and Jinnan Li owns minor shares of Eli Lilly and Company. The other authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study received approval from the relevant ethics committee(s) and was conducted in accordance with the Good Clinical Practices guidelines, in line with the Declaration of Helsinki of 1964, and applicable local laws and regulations. Written informed consent was obtained from all patients before inclusion, and the study was registered at clinical trials. gov (NCT03364309).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}